Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, announced positive preclinical data supporting the activity of SBP-101 in ovarian cancer cell lines.
Panbela Therapeutics, Inc. Completes Enrollment in Its Phase 1b Trial Investigating SBP-101 Combination Therapy for First-Line Metastatic Pancreatic Cancer
Panbela Therapeutics, Inc., formerly Sun Biopharma, a UF startup and clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA).
Sun BioPharma, Inc. Changes Name to Panbela Therapeutics Inc.
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective December 2, 2020.
Sun BioPharma, Inc. Receives FDA Fast Track Designation for SBP-101
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, announced receipt of Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its lead product, SBP-101, being developed for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA) when administered in […]
Sun BioPharma Provides Business Update and Reports Operating Results for FY2019
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic cancer, provided a business update and reports financial results for the year ended December 31, 2019. Sun BioPharma is developing SBP-101, a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance […]
Sun BioPharma, Inc. Presents SBP-101 Phase 1 Clinical Data
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of people with pancreatic cancer, summarized initial Phase 1 clinical data for SBP-101, which was presented in a poster session at the American Society for Clinical Oncology (ASCO) 2020 Gastrointestinal Cancers Symposium. SBP-101 is a proprietary polyamine analogue designed to […]
Sun BioPharma, Inc. Provides an Update on Ongoing Front-Line Pancreatic Cancer Clinical Trial
UF startup Sun BioPharma, Inc., a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, provides an update on the Company’s current clinical trial. Following successful conclusion of the first SBP-101 dose-escalation study in heavily pretreated pancreatic cancer patients that showed SBP-101 could be administered safely as monotherapy, a second Phase 1 […]
Sun BioPharma, Inc. to Present Results of New Pancreatitis Study at American Pancreatic Association Meeting in Miami Beach (Globe Newswire)
UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company specializing in disruptive therapeutics for pancreatic diseases, announced that it will present results of a new study entitled “Effect of SBP-101 in a Mouse Model of Cerulein-induced Acute Pancreatitis” at the American Pancreatic Association meeting in Miami on Nov. 1. The study, performed in collaboration […]
Sun BioPharma Announces Leadership Changes (Globe Newswire)
UF startup Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, announced leadership changes in the organization. David B. Kaysen is stepping down as President, CEO and Board member of Sun BioPharma, Inc. and its wholly owned subsidiary, Sun BioPharma Australia Pty Ltd. Michael T. Cullen, MD, […]
Lion’s Club Hears From Sun BioPharma Founder on Cancer Treatments (IslandReporter)
The featured speaker at the Sanibel-Captiva Lions Club’s dinner meeting, held on Aug. 15 in the Founders Room at The Community House, wants everyone to know more about cancer. “Getting cancer is a big scary deal, but there are things people should know before they make decisions,” Dr. Michael Cullen, founder and chief executive officer […]